TY - JOUR T1 - Comparison of the Time-to-response Between Radiotherapy and Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitors for Advanced Non-small Cell Lung Cancer with <em>EGFR</em> Mutation JF - Anticancer Research JO - Anticancer Res SP - 3279 LP - 3284 VL - 33 IS - 8 AU - HISAO IMAI AU - TAKEHITO SHUKUYA AU - TOSHIAKI TAKAHASHI AU - SAKAE FUJIWARA AU - KEITA MORI AU - AKIRA ONO AU - HIROAKI AKAMATSU AU - TETSUHIKO TAIRA AU - HIROTSUGU KENMOTSU AU - TATEAKI NAITO AU - KYOICHI KAIRA AU - HARUYASU MURAKAMI AU - HIDEYUKI HARADA AU - MASAHIRO ENDO AU - TAKASHI NAKAJIMA AU - NOBUYUKI YAMAMOTO Y1 - 2013/08/01 UR - http://ar.iiarjournals.org/content/33/8/3279.abstract N2 - Background: Patients harboring sensitive epidermal growth factor receptor (EGFR) mutations show a dramatic response to treatment with EGFR tyrosine kinase inhibitors (TKIs). However, there have been no clinical reports in lung cancer patients that compare the time-to-response between radiotherapy and EGFR-TKIs. Patients and Methods: We reviewed 17 and 32 consecutive patients with inoperable stage III/IV NSCLC who harbored sensitive EGFR mutations and who were treated with thoracic radiotherapy with or without chemotherapy and EGFR-TKIs, respectively. Results: There were statistically significant differences in time-to-partial response (PR) with regard to the treatment modalities (radiotherapy vs. EGFR-TKIs, median 57 days vs. 22 days, log-rank test, p=0.008). Conclusion: EGFR-TKIs elicit tumor shrinkage earlier than does radiotherapy in patients with a sensitive EGFR mutation, suggesting that EGFR-TKIs may be useful for early symptom improvement in these patients. ER -